Cellergy Therapeutics
PrivateLast Round
Seed
Oct 14, 2024
Total Funding Raised
$1.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Cellergy Therapeutics is a biotechnology company that is developing mitochondrial transplantation therapies to treat degenerative and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cellergy Therapeutics Comparables
Compare Cellergy Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| cellvie | 85% | |
| Minovia Therapeutics | 84% | |
| PAEAN Biotechnology | 82% | |
Cellergy Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Oct 14, 2024 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 26, 2026
Grew 33% QoQ from 12 to 16 employees.
- Jun 22, 2026
Monthly visitors increased 179% MoM.
Cellergy Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Cellergy Therapeutics's valuation, stock price, and market status.